Current Report Filing (8-k)
August 10 2020 - 7:31AM
Edgar (US Regulatory)
0001001316
false
0001001316
2020-08-10
2020-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported): August 10, 2020
TG
Therapeutics, Inc.
(Exact Name of Registrant
as Specified in Charter)
Delaware
|
|
001-32639
|
|
36-3898269
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal
Executive Offices)
(212) 554-4484
(Registrant's telephone
number, including area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities filed pursuant to Section 12(b) of the Act:
Title of Class
|
Trading Symbol(s)
|
Exchange Name
|
Common Stock
|
TGTX
|
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results
of Operations and Financial Condition.
On
August 10, 2020, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results
of operations for the three and six months ended June 30, 2020. The Company will host an investor conference call today, August
10, 2020, at 8:30am ET, during which the Company will provide a brief overview of its second quarter financial results and provide
a business outlook for the remainder of 2020. A copy of such press release is being furnished as Exhibit 99.1.
Item 9.01. Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
TG Therapeutics, Inc.
|
|
(Registrant)
|
|
|
|
|
Date: August 10, 2020
|
By:
|
/s/ Sean A. Power
|
|
|
Sean A. Power
|
|
|
Chief Financial Officer
|
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024